RxDoctor Payments Data

Zachary Clevenger

Acute Care · Kennesaw, GANPI 1275588071

Payments from drug & device makers

$2,824in general payments, 2019–2025

Across 133 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$531
  • Amgen$325
  • Johnson & Johnson$283
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$282
  • Pfizer$257
  • Novartis$211
  • plus $936 from 16 others

What the payments were for

  • Food & beverage$2,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,824 in reported general payments places this provider in the 90th percentile of 679 acute care providers in Georgia.

See all acute care providers in Georgia

Medicare billing

Part B allowed, 2024
$1,779
Medicare patients
18
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$48,479
EntrestoSacubitril/Valsartan18$10,680
FarxigaDapagliflozin Propanediol17$10,290
Repatha SureclickEvolocumab17$9,267
BrilintaTicagrelor16$8,073
ClopidogrelClopidogrel Bisulfate50$553
Prasugrel Hcl11$518
Metoprolol Succinate86$447
Atorvastatin Calcium65$342
Pantoprazole Sodium16$208
Isosorbide Mononitrate ErIsosorbide Mononitrate23$190
Spironolactone35$177
Hydralazine Hcl14$147
Rosuvastatin Calcium43$139
Nitroglycerin13$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$257$48,47980 claims
AstraZenecaFarxiga, Brilinta$204$18,36233 claims
NovartisEntresto$211$10,68018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 679 acute care providers in Georgia.

Other acute care in Kennesaw

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →